CYLD and hepatocellular carcinoma: We have already shown that CYLD expression in HCC cells can be triggered by the multikinase inhibitor sorafenib, by inhibition of Raf-1, as well as by blockage of the pro-survival kinases MEK and EGFR and identified the recovery of CYLD expression as an interesting approach for overcoming HCC resistance [22].